Real-world prognostic significance of attaining minimal residual disease negativity in newly diagnosed multiple myeloma
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Real-world prognostic significance of attaining minimal residual disease negativity in newly diagnosed multiple myeloma ; volume:15 ; number:1 ; day:17 ; month:2 ; year:2024 ; pages:1-10 ; date:12.2024
Discover oncology ; 15, Heft 1 (17.2.2024), 1-10, 12.2024
- Creator
-
Wang, Jing
Li, Jing
Zhang, Run
Li, Jianyong
Chen, Lijuan
Jin, Yuanyuan
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s12672-024-00891-8
- URN
-
urn:nbn:de:101:1-2404250840382.272794817743
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:49 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Wang, Jing
- Li, Jing
- Zhang, Run
- Li, Jianyong
- Chen, Lijuan
- Jin, Yuanyuan
- SpringerLink (Online service)
Other Objects (12)
Muscle and fat composition in patients with newly diagnosed multiple myeloma
Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma
Maintenance Strategies Post-Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma
Changes in RDW according to prognostic predictors in newly diagnosed multiple myeloma
Single versus tandem autologous stem cell transplantation in newly diagnosed multiple myeloma
Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing
Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma
Treatment Satisfaction and Burden of Illness in Patients with Newly Diagnosed Multiple Myeloma
The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5
Short overview on the current standard of treatment in newly diagnosed multiple myeloma
MRD negativity: considerations for older adults with multiple myeloma
Muscle and fat composition in patients with newly diagnosed multiple myeloma
Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma
Maintenance Strategies Post-Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma
Changes in RDW according to prognostic predictors in newly diagnosed multiple myeloma
Single versus tandem autologous stem cell transplantation in newly diagnosed multiple myeloma
Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing
Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma
Treatment Satisfaction and Burden of Illness in Patients with Newly Diagnosed Multiple Myeloma
The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5
Short overview on the current standard of treatment in newly diagnosed multiple myeloma
MRD negativity: considerations for older adults with multiple myeloma
Muscle and fat composition in patients with newly diagnosed multiple myeloma
Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma
Maintenance Strategies Post-Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma
Changes in RDW according to prognostic predictors in newly diagnosed multiple myeloma
Single versus tandem autologous stem cell transplantation in newly diagnosed multiple myeloma
Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing
Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma
Treatment Satisfaction and Burden of Illness in Patients with Newly Diagnosed Multiple Myeloma
The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5
Short overview on the current standard of treatment in newly diagnosed multiple myeloma